✦ LIBER ✦

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable

✍ Scribed by Peter J. Casterella; Dean J. Kereiakes; Steven R. Steinhubl; Russell E. Raymond; Kandice Kottke-Marchant; Karen Patel; Michelle Mueller; Monique Rosenthal; David J. Moliterno; Paul S. Teirstein

Book ID: 101824660
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 88 KB
Volume: 54
Category: Article
ISSN: 1522-1946
DOI: 10.1002/ccd.1320

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The ultegra rapid platelet-function assa

The ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy

✍ Guy L. Wheeler; Gregory A. Braden; Steven R. Steinhubl; Dean J. Kereiakes; Kandi 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 486 KB

Bivalirudin with planned or provisional

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)

✍ A.Michael Lincoff; Neal S. Kleiman; Kandace Kottke-Marchant; Elizabeth S. Maiers 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Standard Versus Low-Dose Weight-Adjusted

Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization

✍ A.Michael Lincoff; MD; James E. Tcheng; MD; Robert M. Califf; MD; Theodore Bass; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Point-of-care testing shows clinically r

Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention

✍ Michael J. Ray; Darren L. Walters; Nicholas Bett; James Cameron; Peter Wood; Con 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

A randomized two-by-two comparison of hi

A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial

✍ David J. Moliterno;; the TENACITY Steering Committee; Investigators 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

711-3-A Multicenter, Randomized, Double-

711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization

✍ A. Michael Lincoff; James E. Tcheng; Theodore A. Bass; Jeffrey J. Popma; Paul S. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 237 KB